^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ASXL1 mutation + NRAS mutation

    i
    Other names: NRAS1, N-Ras Protein Part 4, Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, NRAS, Neuroblastoma RAS Viral Oncogene Homolog, NRAS Proto-Oncogene, GTPase, ASXL1, ASXL Transcriptional Regulator 1, Additional Sex Combs Like 1, Transcriptional Regulator, Polycomb Group Protein ASXL1, Additional Sex Combs Like Transcriptional Regulator 1, Additional Sex Combs Like 1 (Drosophila), Putative Polycomb Group Protein ASXL1, Additional Sex Combs-Like Protein 1, KIAA0978, BOPS, MDS
    Entrez ID:
    4893; 171023
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    6ms
    Childhood AML Combined with AML1-ETO Fusion Gene and c-KIT or Other Mutations Had Favorable Survival Treated By the C-Huanan AML 2015 Protocol: Study in Multicenter of South of China (ASH 2023)
    Combination of c-KIT or FLT3-ITD or ASXL1 or WT1 or NRAS gene mutations with AML1-ETO fusion gene in Childhood AML treated by the C-HUANAN AML protocol did not affected patients'survival.
    Clinical
    |
    FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • ASXL1 (ASXL Transcriptional Regulator 1) • WT1 (WT1 Transcription Factor)
    |
    NRAS mutation • FLT3-ITD mutation • KIT mutation • ASXL1 mutation • WT1 mutation • ASXL1 mutation + NRAS mutation
    10ms
    Clinical Analysis of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    BPDCN is a highly heterogeneous malignant tumor with a poor prognosis. HSCT, especially allo-HSCT can significantly improve the prognosis of BPDCN patients.
    Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    NRAS mutation • ASXL1 mutation • TET2 mutation • ASXL1 mutation + NRAS mutation
    2years
    Role of the bone marrow immune microenvironment in chronic myelomonocytic leukemia pathogenesis: novel mechanisms and insights into clonal propagation. (PubMed, Leuk Lymphoma)
    Somatic mutational events in CMML such as ASXL1 and NRAS mutations cooperate to induce T cell exhaustion and contribute toward disease progression to acute myeloid leukemia (AML). In this review, we explore the role of aging-induced alterations in the BM immune microenvironment, aberrant innate immune and proinflammatory signaling, and the adaptive immune system in CMML.
    Journal • IO biomarker
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • ASXL1 (ASXL Transcriptional Regulator 1) • CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    NRAS mutation • ASXL1 mutation • ASXL1 mutation + NRAS mutation
    over2years
    Asxl1loss cooperates with oncogenic Nras in mice to reprogram immune microenvironment and drive leukemic transformation. (PubMed, Blood)
    Combined inhibition of MEK and BET led to downregulation of Flt3 and AP-1 expression, partial restoration of the immune microenvironment, enhancement of CD8+ T cell cytotoxicity, and prolonged survival in NA-AML mice. Our study suggests that combined targeted therapy and immunotherapy may be beneficial for treating secondary AML with concurrent ASXL1 and NRAS mutations.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD86 (CD86 Molecule)
    |
    NRAS mutation • ASXL1 mutation • PD-1 overexpression • PD-1 expression • NRAS G12 • ASXL1 mutation + NRAS mutation
    almost3years
    A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. (PubMed, Blood Adv)
    Predictions were superior compared with existing scores designed for the nontransplant setting, which resulted in significant risk reclassification. This CMML transplant score, which incorporated mutation and clinical information, was prognostic in patients specifically undergoing transplantation and may facilitate personalized counseling.
    Clinical • Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • ASXL1 (ASXL Transcriptional Regulator 1)
    |
    NRAS mutation • ASXL1 mutation • ASXL1 mutation + NRAS mutation